Host indoleamine 2,3-dioxygenase: Contribution to systemic acquired tumor tolerance

Immunological Investigations

Volumn 41, Issue 6-7, 2012, Pages 765-797

  Johnson, Theodore S ^a,b   Munn, David H ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b Immunotherapy Center   (United States)

Author keywords

Dioxygenase; Host; IDO; Indoleamine; Indoleamine 2,3 dioxygenase; Tolerance; Treg; Tumor

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; INDOLEAMINE 2,3 DIOXYGENASE; PACLITAXEL; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; TEMOZOLOMIDE; TRYPTOPHAN 2,3 DIOXYGENASE; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL MATURATION; CELL STRESS; CLINICAL TRIAL (TOPIC); CLONAL ANERGY; CROSS PRESENTATION; DENDRITIC CELL; DRUG RESISTANCE; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HOST CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; IN VITRO STUDY; INNATE IMMUNITY; NATURAL HOST; NITRATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRYPTOPHAN METABOLISM; TUMOR MICROENVIRONMENT; TUMOR TOLERANCE; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DENDRITIC CELLS; ENZYME INHIBITORS; HUMANS; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; MACROPHAGES; MICE; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TRYPTOPHAN;

EID: 84866948348     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2012.689405     Document Type: Article

References (211)

1. Adam, R., Russing, D., Adams, O., Ailyati, A., Sik Kim, K., Schroten, H., Daubener, W.(2005). Role of human brain microvascular endothelial cells during central nervoussystem infection. Significance of indoleamine 2,3-dioxygenase in antimicrobialdefence and immunoregulation. Thromb. Haemost. 94: 341-346.
2. Alexander, A. M. Crawford, M., Bertera, S., Rudert, W. A., Takikawa, O., Robbins, P. D.,Trucco, M. (2002). Indoleamine 2,3-dioxygenase expression in transplanted NODIslets prolongs graft survival after adoptive transfer of diabetogenic splenocytes.Diabetes 51: 356-365.
3. Arefayene, M., Philips, S., Cao, D., Mamidipalli, S., Desta, Z., Flockhart, D. A., Wilkes,D. S., Skaar, T. C. (2009). Identification of genetic variants in the human indoleamine2,3-dioxygenase (IDO1) gene, which have altered enzyme activity.Pharmacogenet. Genom. 19: 464-476.
4. Attwood, J. T., Munn, D. H. Macrophage suppression of T cell activation: a potentialmechanism of peripheral tolerance. Int. Rev. Immunol. 1999;18: 515-525.
5. Baban, B., Chandler, P., McCool, D., Marshall, B., Munn, D. H., Mellor, A. L. (2004).Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cellsduring murine gestation and is maternal genome specific. J. Reprod. Immunol.61: 67-77.
6. Baban, B., Chandler, P. R., Johnson, B. A., 3rd, Huang, L., Li, M., Sharpe, M. L., Francisco,L. M., Sharpe, A. H., Blazar, B. R., Munn, D. H., Mellor, A. L. (2011). Physiologiccontrol of IDO competence in splenic dendritic cells. J. Immunol. 187: 2329-2335.
7. Baban, B., Chandler, P. R., Sharma, M. D., Pihkala, J., Koni, P. A., Munn, D. H., Mellor,A. L. (2009). IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J. Immunol. 183: 2475-2483.
8. Baban, B., Hansen, A. M., Chandler, P. R., Manlapat, A., Bingaman, A., Kahler, D. J.,Munn, D. H. Mellor, A. L. (2005). A minor population of splenic dendritic cellsexpressing CD19 mediates IDO-dependent T cell suppression via type I IFN signalingfollowing B7 ligation. Int. Immunol. 17: 909-919.
9. Ball, H. J., Sanchez-Perez, A., Weiser, S., Austin, C. J., Astelbauer, F., Miu, J.,McQuillan, J. A., Stocker, R., Jermiin, L. S., Hunt, N. H. (2007). Characterizationof an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene396: 203-213.
10. Ball, H. J., Yuasa, H. J., Austin, C. J., Weiser, S., Hunt, N. H. (2009). Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int. J. Biochem. Cell Biol.41: 467-471.
11. Bankoti, J., Rase, B., Simones, T., Shepherd, D. M. (2010). Functional and phenotypiceffects of AhR activation in inflammatory dendritic cells. Toxicol. Appl. Pharmacol.246: 18-28.
12. Belladonna, M. L., Orabona, C., Grohmann, U., Puccetti, P. (2009). TGF-beta and kynureninesas the key to infectious tolerance. Trends Mol. Med. 15: 41-49.
13. Belladonna, M. L., Volpi, C., Bianchi, R., Vacca, C., Orabona, C., Pallotta, M. T., Boon, L.,Gizzi, S., Fioretti, M. C., Grohmann, U., Puccetti, P. (2008). Cutting edge: AutocrineTGF-beta sustains default tolerogenesis by IDO-competent dendritic cells.J. Immunol. 181: 5194-5198.
14. Beutelspacher, S. C., Pillai, R., Watson, M. P., Tan, P. H., Tsang, J., McClure, M. O.,George, A. J., Larkin, D. F. (2006a). Function of indoleamine 2,3-dioxygenase incorneal allograft rejection and prolongation of allograft survival by over-expression.Eur. J. Immunol. 36: 690-700.
15. Beutelspacher, S. C., Tan, P. H., McClure, M. O., Larkin, D. F., Lechler, R. I., George, A. J.(2006b). Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implicationsfor the control of alloresponses. Am. J. Transplant. 6: 1320-1330.
16. Black, C. A., Rohan, L. C., Cost, M., Watkins, S. C., Draviam, R., Alber, S., Edwards, R. P.(2000). Vaginal mucosa serves as an inductive site for tolerance. J. Immunol.165: 5077-5083.
17. Boasso, A., Herbeuval, J. P., Hardy, A. W., Anderson, S. A., Dolan, M. J., Fuchs, D.,Shearer, G. M. (2007). HIV inhibits CD4 + T-cell proliferation by inducing indoleamine2,3-dioxygenase in plasmacytoid dendritic cells. Blood 109: 3351-3359.
18. Bodaghi, B., Goureau, O., Zipeto, D., Laurent, L., Virelizier, J. L., Michelson, S. (1999).Role of IFN-gamma-induced indoleamine 2,3 dioxygenase and inducible nitric oxidesynthase in the replication of human cytomegalovirus in retinal pigment epithelialcells. J. Immunol. 162: 957-964.
19. Bonertz, A., Weitz, J., Pietsch, D. H., Rahbari, N. N., Schlude, C., Ge, Y., Juenger, S.,Vlodavsky, I., Khazaie, K., Jaeger, D., Reissfelder, C., Antolovic, D., Aigner, M.,Koch, M., Beckhove, P. (2009). Antigen-specific Tregs control T cell responses againsta limited repertoire of tumor antigens in patients with colorectal carcinoma. J. Clin.Invest. 119: 3311-3321.
20. Boon, T., van der Bruggen, P. (1996). Human tumor antigens recognized by T lymphocytes.J. Exp. Med. 183: 725-9.
21. Brandacher, G., Perathoner, A., Ladurner, R., Schneeberger, S., Obrist, P., Winkler, C.,Werner, E. R., Werner-Felmayer, G., Weiss, H. G., Gobel, G., Margreiter, R.,Konigsrainer, A., Fuchs, D., Amberger, A. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: Effect on tumor-infiltrating T cells.Clin. Cancer Res. 2006;12: 1144-51.
22. Braun, D., Longman, R. S., Albert,M. L. (2005). A two-step induction of indoleamine 2,3dioxygenase (IDO) activity during dendritic-cell maturation. Blood2005;106: 2375-81.
23. Brenk, M., Scheler, M., Koch, S., Neumann, J., Takikawa, O., Hacker, G., Bieber, T., vonBubnoff, D. (2009). Tryptophan deprivation induces inhibitory receptors ILT3 andILT4 on dendritic cells favoring the induction of human CD4 +CD25 + Foxp3 + Tregulatory cells. J. Immunol. 183: 145-154.
24. Brody, J. R., Costantino, C. L., Berger, A. C., Sato, T., Lisanti, M. P., Yeo, C. J., Emmons,R. V., Witkiewicz, A. K. (2009). Expression of indoleamine 2,3-dioxygenase in metastaticmalignant melanoma recruits regulatory T cells to avoid immune detectionand affects survival. Cell Cycle 8: 1930-1934.
25. Calzascia, T., Loh, J. M., Di Berardino-Besson, W., Masson, F., Guillaume, P., Burkhardt,K., Herrera, P. L., Dietrich, P. Y., Walker, P. R. (2008). Peripheral tolerance limitsCNS accumulation of CD8 T cells specific for an antigen shared by tumor cells andnormal astrocytes. Glia 56: 1625-1636.
26. Chamuleau, M. E., van de Loosdrecht, A. A., Hess, C. J., Janssen, J. J., Zevenbergen, A.,Delwel, R., Valk, P. J., Lowenberg, B., Ossenkoppele, G. J. (2008). High INDO(indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemicpatients predicts poor clinical outcome. Haematologica 93: 1894-1898.
27. Chang, M. Y., Smith, C., Duhadaway, J. B., Pyle, J. R., Boulden, J., Peralta Soler, A.,Muller, A. J., Laury-Kleintop LD, Prendergast GC. Cardiac and gastrointestinalliabilities caused by deficiency in the immune modulatory enzyme indoleamine 2,3-dioxygenase. Cancer Biol Ther. 2011;12.
28. Cheever, M. A. (2008). Twelve immunotherapy drugs that could cure cancers. Immunol.Rev. 222: 357-368.
29. Chen, W., Liang, X., Peterson, A. J., Munn, D. H., Blazar, B. R. (2008). The indoleamine2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-inducedadaptive T regulatory cell generation. J. Immunol. 181: 5396-5404.
30. Chung, D. J., Rossi, M., Romano, E., Ghith, J., Yuan, J., Munn, D. H., Young, J. W. (2009).Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendriticcells expand potent autologous regulatory T cells. Blood 114: 555-563.
31. Chung, K. T., Gadupudi, G. S. (2011). Possible roles of excess tryptophan metabolites incancer. Environ. Mol. Mutagen 52: 81-104.
32. Ciorba, M. A., Bettonville, E. E., McDonald, K. G., Metz, R., Prendergast, G. C.,Newberry, R. D., Stenson, W. F. (2010). Induction of IDO-1 by immunostimulatoryDNA limits severity of experimental colitis. J. Immunol. 184: 3907-3916.
33. Clark, C. E., Beatty, G. L., Vonderheide, R. H. (2009). Immunosurveillance of pancreaticadenocarcinoma: insights from genetically engineered mouse models of cancer.Cancer Lett. 279: 1-7.
34. Cobbold, S. P., Adams E., Farquhar, C. A., Nolan, K. F., Howie, D., Lui, K. O., Fairchild,P. J., Mellor, A. L., Ron, D., Waldmann, H. (2009). Infectious tolerance via theconsumption of essential amino acids and mTOR signaling. Proc. Natl. Acad. Sci.USA 106: 12055-12060.
35. Cochran, A. J., Huang, R. R., Lee, J., Itakura, E., Leong, S. P., Essner, R. (2006).Tumour-induced immune modulation of sentinel lymph nodes. Nat. Rev.Immunol. 6: 659-670.
36. Colombo, M. P., Piconese, S. (2007). Regulatory-T-cell inhibition versus depletion: theright choice in cancer immunotherapy. Nat. Rev. Cancer 7: 880-887.
37. Corm, S., Berthon, C., Imbenotte, M., Biggio, V., Lhermitte, M., Dupont, C., Briche, I.,Quesnel, B. (2009). Indoleamine 2,3-dioxygenase activity of acute myeloid leukemiacells can be measured from patients' sera by HPLC and is inducible by IFN-gamma.Leuk. Res. 33: 490-494.
38. Cuenca, A., Cheng, F., Wang, H., Brayer, J., Horna, P., Gu, L., Bien, H., Borrello,I. M., Levitsky, H. I., Sotomayor, E. M. (2003). Extra-lymphatic solid tumorgrowth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.Cancer Res. 63: 9007-9015.
39. Cuffy, M. C., Silverio, A. M., Qin, L., Wang, Y., Eid, R., Brandacher, G., Lakkis, F. G.,Fuchs, D., Pober, J. S., Tellides, G. (2007). Induction of indoleamine 2,3-dioxygenasein vascular smooth muscle cells by interferon-gamma contributes to medial immunoprivilege.J. Immunol. 179: 5246-5254.
40. Curiel, T. J. (2008). Regulatory T cells and treatment of cancer. Curr. Opin. Immunol.20: 241-246.
41. Curti, A., Aluigi, M., Pandolfi, S., Ferri, E., Isidori, A., Salvestrini, V., Durelli, I.,Horenstein, A. L., Fiore, F., Massaia, M., Piccioli, M., Pileri, S. A., Zavatto, E.,D'Addio, A., Baccarani, M., Lemoli, R. M. (2007a). Acute myeloid leukemia cellsconstitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase.Leukemia 21: 353-355.
42. Curti, A., Pandolfi, S., Valzasina, B., Aluigi, M., Isidori, A., Ferri, E., Salvestrini, V.,Bonanno, G., Rutella, S., Durelli, I., Horenstein, A. L., Fiore, F., Massaia, M.,Colombo, M. P., Baccarani, M., Lemoli, R. M. (2007b). Modulation of tryptophancatabolism by human leukemic cells results in the conversion of CD25-into CD25 + Tregulatory cells. Blood 109: 2871-2877.
43. Darrasse-Jeze, G., Bergot, A. S., Durgeau, A., Billiard, F., Salomon, B. L., Cohen, J. L.,Bellier, B., Podsypanina, K., Klatzmann, D. (2009). Tumor emergence is sensed byself-specific CD44hi memory Tregs that create a dominant tolerogenic environmentfor tumors in mice. J. Clin. Invest. 119: 2648-2662.
44. Daubener, W., Remscheid, C., Nockemann, S., Pilz, K., Seghrouchni, S., Mackenzie, C.,Hadding, U. (1996). Anti-parasitic effector mechanisms in human brain tumorcells: role of interferon-gamma and tumor necrosis factor-alpha. Eur. J. Immunol.26: 487-492.
45. Desvignes, L., Ernst, J. D. (2009). Interferon-gamma-responsive nonhematopoieticcells regulate the immune response to Mycobacterium tuberculosis. Immunity31: 974-985.
46. DiNatale, B. C., Murray, I. A., Schroeder, J. C., Flaveny, C. A., Lahoti, T. S., Laurenzana,E. M., Omiecinski, C. J., Perdew, G. H. (2010). Kynurenic acid is a potent endogenousaryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in thepresence of inflammatory signaling. Toxicol. Sci. 115: 89-97.
47. Divanovic, S., Sawtell, N. M., Trompette, A., Warning, J. I., Dias, A., Cooper, A. M., Yap,G. S., Arditi, M., Shimada, K., Duhadaway, J. B., Prendergast, G. C., Basaraba, R. J.,Mellor, A. L., Munn, D. H., Aliberti, J., Karp, C. L. (2012). Opposing biologicalfunctions of tryptophan catabolizing enzymes during intracellular infection. JInfect Dis. 205: 152-161.
48. Duluc, D., Delneste, Y., Tan, F., Moles, M. P, Grimaud, L., Lenoir, J., Preisser, L., Anegon,I., Catala, L., Ifrah, N., Descamps, P., Gamelin, E., Gascan, H., Hebbar, M., Jeannin,P. (2007).Tumor-associated leukemia inhibitory factor and IL-6 skew monocytedifferentiation into tumor-associated macrophage-like cells. Blood 110: 4319-4330.
49. Ercolini, A. M., Ladle, B. H., Manning, E. A., Pfannenstiel, L. W., Armstrong, T. D.,Machiels, J. P., Bieler, J. G., Emens, L. A., Reilly, R. T., Jaffee, E. M. (2005).Recruitment of latent pools of high-avidity CD8( +) T cells to the antitumor immuneresponse. J. Exp. Med. 201: 1591-1602.
50. Fallarino, F., Grohmann, U., You, S., McGrath, B. C., Cavener, D. R., Vacca, C., Orabona,C., Bianchi, R., Belladonna, M. L., Volpi, C., Santamaria, P., Fioretti, M. C., Puccetti,P. (2006). The combined effects of tryptophan starvation and tryptophan catabolitesdown-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naiveT cells. J. Immunol. 176: 6752-6761.
51. Fallarino, F., Vacca, C., Orabona, C., Belladonna, M. L., Bianchi, R., Marshall, B., Keskin,D. B., Mellor, A. L., Fioretti, M. C., Grohmann, U., Puccetti, P. (2002). Functionalexpression of indoleamine 2,3-dioxygenase by murine CD8 alpha( +) dendritic cells.Int. Immunol. 14: 65-68.
52. Favre, D., Mold, J., Hunt, P. W., Kanwar, B., Loke, P., Seu, L., Barbour, J. D., Lowe,M. M., Jayawardene, A., Aweeka, F., Huang, Y., Douek, D. C., Brenchley, J. M.,Martin, J. N., Hecht, F. M., Deeks, S. G., McCune, J. M. (2010). Tryptophan catabolismby indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory Tcells in HIV disease. Sci. Transl. Med. 2: 32ra36.
53. Feder-Mengus, C., Wyler, S., Hudolin, T., Ruszat, R., Bubendorf, L., Chiarugi, A., Pittelli,M., Weber, W. P., Bachmann, A., Gasser, T. C., Sulser, T., Heberer, M., Spagnoli,G. C., Provenzano, M. (2008). High expression of indoleamine 2,3-dioxygenase genein prostate cancer. Eur. J. Cancer 44: 2266-2275.
54. Ferdinande, L., Demetter, P., Perez-Novo, C., Waeytens, A., Taildeman, J., Rottiers, I.,Rottiers, P., De Vos, M., Cuvelier, C. A. (2008). Inflamed intestinal mucosa features aspecific epithelial expression pattern of indoleamine 2,3-dioxygenase. Int.J. Immunopathol. Pharmacol. 21: 289-295.
55. Francois, M., Romieu-Mourez, R., Li, M., Galipeau, J. (2012). Human MSC suppressioncorrelates with cytokine induction of indoleamine 2,3-dioxygenase and bystanderM2macrophage differentiation. Mol Ther. 20: 187-195.
56. Fuchs, D., Moller, A. A., Reibnegger, G., Stockle, E., Werner, E. R., Wachter, H. (1990).Decreased serum tryptophan in patients with HIV-1 infection correlates withincreased serum neopterin and with neurologic/psychiatric symptoms. J. Acquir.Immune Defic. Syndr. 3: 873-876.
57. Fujigaki, H., Saito, K., Lin, F., Fujigaki, S., Takahashi, K., Martin, B. M., Chen, C. Y.,Masuda, J, Kowalak, J., Takikawa, O., Seishima, M., Markey, S. P. (2006). Nitrationand inactivation of IDO by peroxynitrite. J. Immunol. 176: 372-379.
58. Gerlini, G., Di Gennaro, P., Mariotti, G., Urso, C., Chiarugi, A., Pimpinelli, N.,Borgognoni, L. (2010). Indoleamine 2,3-dioxygenase + cells correspond to theBDCA2 + plasmacytoid dendritic cells in human melanoma sentinel nodes.J. Invest. Dermatol. 130: 898-901.
59. Grant, R. S., Naif, H., Thuruthyil, S. J., Nasr, N., Littlejohn, T., Takikawa, O., Kapoor, V.(2000). Induction of indolamine 2,3-dioxygenase in primary human macrophages byhuman immunodeficiency virus type 1 is strain dependent. J. Virol. 74: 4110-4115.
60. Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro,P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., Puccetti, P. (2002). CTLA-4-Igregulates tryptophan catabolism in vivo. Nat. Immunol. 3: 1097-1101.
61. Grohmann, U., Volpi, C., Fallarino, F., Bozza, S., Bianchi, R., Vacca, C., Orabona, C.,Belladonna, M. L., Ayroldi, E., Nocentini, G., Boon, L., Bistoni, F., Fioretti, M. C.,Romani, L., Riccardi, C., Puccetti, P. (2007). Reverse signaling through GITR ligandenables dexamethasone to activate IDO in allergy. Nat. Med. 13: 579-586.
62. Gu, T., Rowswell-Turner, R. B., Kilinc, M. O., Egilmez, N. K. (2010). Central role ofIFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunity. Cancer Res. 70: 129-138.
63. Guillemin, G. J. (2012) Quinolinic acid, the inescapable neurotoxin. FEBS J., in press.
64. Guillonneau, C., Hill, M., Hubert, F. X., Chiffoleau, E., Herve, C., Li, X. L., Heslan, M.,Usal, C., Tesson, L., Menoret, S., Saoudi, A., Le Mauff, B., Josien, R., Cuturi, M. C.,Anegon, I. (2007). CD40Ig treatment results in allograft acceptance mediated byCD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J. Clin. Invest.117: 1096-1106.
65. Gurtner GJ, Newberry RD, Schloemann SR, McDonald KG, Stenson WF. Inhibition ofindoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice.Gastroenterology. 2003;125: 1762-73.
66. Hainz, U., Jurgens, B., Wekerle, T., Seidel, M. G., Heitger, A. (2007). Indoleamine2,3-dioxygenase in hematopoietic stem cell transplantation. Curr. Drug Metab.8: 267-272.
67. Hainz, U., Obexer, P., Winkler, C., Sedlmayr, P., Takikawa, O., Greinix, H., Lawitschka,A., Potschger, U., Fuchs, D., Ladisch, S., Heitger, A. (2005). Monocyte-mediated Tcellsuppression and augmented monocyte tryptophan catabolism after humanhematopoietic stem-cell transplantation. Blood 105: 4127-4134.
68. Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M.,Hyams, D. M., Gomez, H., Bastholt, L., Chasalow, S. D., Berman, D. (2011). Aprospective phase II trial exploring the association between tumor microenvironmentbiomarkers and clinical activity of ipilimumab in advanced melanoma.J. Transl. Med. 9: 204.
69. Hansen, A. M., Ball, H. J., Mitchell, A. J., Miu, J., Takikawa, O., Hunt, N. H. (2004).Increased expression of indoleamine 2,3-dioxygenase in murine malaria infection ispredominantly localised to the vascular endothelium. Int. J. Parasitol. 34: 1309-1319.
70. Harrington, L., Srikanth, C. V., Antony, R., Rhee, S. J., Mellor, A. L., Shi, H. N., Cherayil,B. J. (2008). Deficiency of indoleamine 2,3-dioxygenase enhances commensalinducedantibody responses and protects against Citrobacter rodentium-inducedcolitis. Infect. Immun. 76: 3045-3053.
71. Hayashi, T., Beck, L., Rossetto, C., Gong, X., Takikawa, O., Takabayashi, K., Broide,D. H., Carson, D. A., Raz, E. (2004). Inhibition of experimental asthma by indoleamine2,3-dioxygenase. J Clin Invest. 114: 270-279.
72. Hayashi, T., Mo, J. H., Gong, X., Rossetto, C., Jang, A., Beck, L., Elliott, G. I., Kufareva, I.,Abagyan, R., Broide, D. H., Lee, J., Raz, E. (2007). 3-Hydroxyanthranilic acid inhibitsPDK1 activation and suppresses experimental asthma by inducing T cell apoptosis.Proc. Natl. Acad. Sci. USA 104: 18619-18624.
73. Haynes, N. M., van der Most, R. G., Lake, R. A., Smyth, M. J. (2008). Immunogenicanti-cancer chemotherapy as an emerging concept. Curr. Opin. Immunol.2008;20: 545-557.
74. Herbert, A., Ng, H., Jessup, W., Kockx, M., Cartland, S., Thomas, S. R., Hogg, P. J.,Wargon, O. (2011). Hypoxia regulates the production and activity of glucosetransporter-1 and indoleamine 2,3-dioxygenase in monocyte-derived endotheliallikecells: possible relevance to infantile haemangioma pathogenesis. Br.J. Dermatol. 164: 308-315.
75. Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M.,Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., Schreiber, R. D.,Murphy, T. L., Murphy, K. M. (2008). Batf3 deficiency reveals a critical role forCD8alpha + dendritic cells in cytotoxic T cell immunity. Science 322: 1097-1100.
76. Holmes, E. W. (1998). Expression and regulation of interferon-gamma- induced tryptophancatabolism in cultured skin fibroblasts. J. Interferon Cytokine Res. 18: 509-520.
77. Hou, D. Y., Muller, A. J., Sharma, M. D., DuHadaway, J., Banerjee, T., Johnson, M.,Mellor, A. L., Prendergast, G. C., Munn, D. H. (2007). Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlateswith antitumor responses. Cancer Res. 67: 792-801.
78. Huang, A., Fuchs, D., Widner, B., Glover, C., Henderson, D. C., Allen-Mersh, T. G. (2002).Serum tryptophan decrease correlates with immune activation and impaired qualityof life in colorectal cancer. Br. J. Cancer 86: 1691-1696.
79. Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., Levitsky, H. (1994).Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.Science 264: 961-965.
80. Hwu, P., Du, M. X., Lapointe, R., Do, M., Taylor, M. W., Young, H. A. (2000). Indoleamine2,3-dioxygenase production by human dendritic cells results in the inhibition of T cellproliferation. J. Immunol. 164: 3596-3599.
81. Ino, K., Yamamoto, E., Shibata, K., Kajiyama, H., Yoshida, N., Terauchi, M., Nawa, A.,Nagasaka, T., Takikawa, O., Kikkawa, F. (2008). Inverse correlation betweentumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytesin endometrial cancer: its association with disease progression and survival.Clin. Cancer Res. 14: 2310-2317.
82. Ino, K., Yoshida, N., Kajiyama, H., Shibata, K., Yamamoto, E., Kidokoro, K., Takahashi,N., Terauchi, M., Nawa, A., Nomura, S., Nagasaka, T., Takikawa, O., Kikkawa, F.(2006). Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrialcancer. Br. J. Cancer 2006;95: 1555-1561.
83. Ito, H., Hoshi, M., Ohtaki, H., Taguchi, A., Ando, K., Ishikawa, T., Osawa, Y., Hara, A.,Moriwaki, H., Saito, K., Seishima, M. (2010). Ability of IDO to attenuate liver injuryin alpha-galactosylceramide-induced hepatitis model. J. Immunol. 185: 4554-4560.
84. Ito, M., Ogawa, K., Takeuchi, K., Nakada, A., Heishi, M., Suto, H., Mitsuishi, K., Sugita,Y., Ogawa, H., Ra, C. (2004). Gene expression of enzymes for tryptophan degradationpathway is upregulated in the skin lesions of patients with atopic dermatitis orpsoriasis. J. Dermatol. Sci. 36: 157-164.
85. Jackman, K. A., Brait, V. H., Wang, Y., Maghzal, G. J., Ball, H. J., McKenzie, G., De Silva,T. M., Stocker, R., Sobey, C. G. (2011). Vascular expression, activity and function ofindoleamine 2,3-dioxygenase-1 following cerebral ischaemia-reperfusion in mice.Naunyn Schmiedebergs Arch Pharmacol. 383: 471-481.
86. Jalili, R. B., Forouzandeh, F., Moeenrezakhanlou, A., Rayat, G. R., Rajotte, R. V., Uludag,H., Ghahary, A. (2009). Mouse pancreatic islets are resistant to indoleamine 2,3dioxygenase-induced general control nonderepressible-2 kinase stress pathway andmaintain normal viability and function. Am. J. Pathol. 174: 196-205.
87. Jasperson, L. K., Bucher, C., Panoskaltsis-Mortari, A., Mellor, A. L., Munn, D. H., Blazar,B. R. (2009). Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality.Blood 114: 5062-5070.
88. Jasperson, L. K., Bucher, C., Panoskaltsis-Mortari, A., Taylor, P. A., Mellor, A. L., Munn,D. H., Blazar, B. R. (2008). Indoleamine 2,3-dioxygenase is a critical regulator ofacute graft-versus-host disease lethality. Blood 111: 3257-3265.
89. Jia, L., Schweikart, K., Tomaszewski, J., Page, J. G., Noker, P. E., Buhrow, S. A., Reid,J. M., Ames, M. M., Munn, D. H. (2008). Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Food Chem.Toxicol. 46: 203-211.
90. Johnson, B. A., 3rd, Kahler, D. J., Baban, B., Chandler, P. R., Kang, B., Shimoda, M.,Koni, P. A., Pihkala, J., Vilagos, B., Busslinger, M., Munn, D. H., Mellor, A. L. (2010).B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine2,3-dioxygenase. Proc. Natl. Acad. Sci. USA 107: 10644-10648.
91. Johnson, T. S., Munn, D. H., Maria, B. L. (2012). Modulation of tumor tolerance inprimary central nervous system malignancies. Clin. Dev. Immunol. 2012: 1-14.
92. Kallberg, E., Wikstrom, P., Bergh, A., Ivars, F., Leanderson, T. (2010). Indoleamine 2,3-dioxygenase (IDO) activity influence tumor growth in the TRAMP prostate cancermodel. Prostate 70: 1461-1470.
93. Koblish, H. K., Hansbury, M. J., Bowman, K. J., Yang, G., Neilan, C. L., Haley, P. J.,Burn, T. C., Waeltz, P., Sparks, R. B., Yue, E. W., Combs, A. P., Scherle, P. A., Vaddi,K., Fridman, J. S. (2010). Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth ofIDO-expressing tumors. Mol. Cancer Ther. 9: 489-498.
94. Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O.,Gopinathan, A., Tuveson, D. A., Fearon, D. T. (2010). Suppression of antitumorimmunity by stromal cells expressing fibroblast activation protein-alpha. Science330: 827-830.
95. Kwidzinski, E., Bechmann, I. (2007). IDO expression in the brain: a double-edged sword.J Mol Med (Berl). 85: 1351-1359.
96. Kwidzinski, E., Bunse, J., Aktas, O., Richter, D., Mutlu, L., Zipp, F., Nitsch, R.,Bechmann, I. (2005). Indolamine 2,3-dioxygenase is expressed in the CNS anddown-regulates autoimmune inflammation. FASEB J. 19: 1347-9.
97. Kwidzinski, E., Bunse, J., Kovac, A. D., Ullrich, O., Zipp, F., Nitsch, R., Bechmann, I.(2003). IDO (indolamine 2,3-dioxygenase) expression and function in the CNS. Adv.Exp. Med. Biol. 527: 113-8.
98. Lake, R. A., Robinson, B. W. (2005). Immunotherapy and chemotherapy-a practicalpartnership. Nat. Rev. Cancer 5: 397-405.
99. Lee, J. H., Torisu-Itakara, H., Cochran, A. J., Kadison, A., Huynh, Y., Morton, D. L.,Essner, R. (2005). Quantitative analysis of melanoma-induced cytokine-mediatedimmunosuppression in melanoma sentinel nodes. Clin. Cancer Res. 11: 107-112.
100. Lee, J. R., Dalton, R. R., Messina, J. L., Sharma, M. D., Smith, D. M., Burgess, R. E.,Mazzella, F., Antonia, S. J., Mellor, A. L., Munn, D. H. (2003). Pattern of recruitmentof immunoregulatory antigen-presenting cells in malignant melanoma. Lab. Invest.83: 1457-1466.
101. Liu, H., Liu, L., Fletcher, B. S., Visner, G.A. (2006). Novel action of indoleamine 2,3-dioxygenase attenuating acute lung allograft injury. Am. J. Respir. Crit. Care Med.173: 566-572.
102. Liu, X., Shin, N., Koblish, H. K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M. J.,Thomas, B., Rupar, M., Waeltz, P., Bowman, K. J., Polam, P., Sparks, R. B., Yue,E. W., Li, Y., Wynn, R., Fridman, J. S., Burn, T. C., Combs, A. P., Newton, R. C.,Scherle, P. A. (2010). Selective inhibition of IDO1 effectively regulates mediators ofantitumor immunity. Blood 115: 3520-3530.
103. Lo, B. K., Jalili, R. B., Zloty, D., Ghahary, A., Cowan, B., Dutz, J. P., Carr, N., Shapiro,J., McElwee, K. J. (2011). CXCR3 ligands promote expression of functional indoleamine2,3-dioxygenase in basal cell carcinoma keratinocytes. Br. J. Dermatol.165: 1030-1036.
104. Lob, S., Konigsrainer, A., Rammensee, H. G., Opelz, G., Terness, P. (2009a). Inhibitors ofindoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?Nat. Rev. Cancer 9: 445-452.
105. Lob, S., Konigsrainer, A., Schafer, R., Rammensee, H. G., Opelz, G., Terness, P. (2008).Levo-but not dextro-1-methyl tryptophan abrogates the IDO activity of humandendritic cells. Blood 111: 2152-2154.
106. Lob, S., Konigsrainer, A., Zieker, D., Brucher, B. L., Rammensee, H. G., Opelz, G.,Terness, P. (2009b). IDO1 and IDO2 are expressed in human tumors: levo-but notdextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol.Immunother. 58: 153-157.
107. Lurquin, C., Lethe, B., De Plaen, E., Corbiere, V., Theate, I., van Baren, N., Coulie, P. G.,Boon, T. (2005). Contrasting frequencies of antitumor and anti-vaccine T cells inmetastases of a melanoma patient vaccinated with a MAGE tumor antigen. J. Exp.Med. 201: 249-257.
108. Ma, Y., Kepp, O., Ghiringhelli, F., Apetoh, L., Aymeric, L., Locher, C., Tesniere, A.,Martins, I., Ly, A., Haynes, N. M., Smyth, M. J., Kroemer, G., Zitvogel. L. (2010).Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin. Immunol.22: 113-124.
109. Maksimow, M., Miiluniemi, M., Marttila-Ichihara, F., Jalkanen, S., Hanninen, A. (2006).Antigen targeting to endosomal pathway in dendritic cell vaccination activatesregulatory T cells and attenuates tumor immunity. Blood 108: 1298-1305.
110. Malone, D. G., Dolan, P. W., Brown, R. R., Kalayoglu, M. V., Arend, R. A., Byrne, G. I.,Ozaki, Y. (1994). Interferon gamma induced production of indoleamine 2,3 dioxygenasein cultured human synovial cells. J. Rheumatol. 21: 1011-1019.
111. Manches, O., Munn, D., Fallahi, A., Lifson, J., Chaperot, L., Plumas, J., Bhardwaj, N.(2008). HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine2,3-dioxygenase-dependent mechanism. J. Clin. Invest. 118: 3431-3439.
112. Manlapat, A. K., Kahler, D. J., Chandler, P. R., Munn, D. H., Mellor, A. L. (2007). Cellautonomouscontrol of interferon type I expression by indoleamine 2,3-dioxygenasein regulatory CD19 + dendritic cells. Eur. J. Immunol. 37: 1064-1071.
113. Mansfield, A. S., Heikkila, P. S., Vaara, A. T., von Smitten, K. A., Vakkila, J. M.,Leidenius, M. H. (2009). Simultaneous Foxp3 and IDO expression is associatedwith sentinel lymph node metastases in breast cancer. BMC Cancer 9: 231.
114. Marshall, N. B., Kerkvliet, N. I. (2010). Dioxin and immune regulation: emerging role ofaryl hydrocarbon receptor in the generation of regulatory T cells. Ann. NY Acad. Sci.1183: 25-37.
115. Matteoli, G., Mazzini, E., Iliev, I. D., Mileti, E., Fallarino, F., Puccetti, P., Chieppa, M.,Rescigno, M. (2010). Gut CD103 + dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral toleranceinduction. Gut 59: 595-604.
116. Mellor, A. L., Baban, B., Chandler, P., Marshall, B., Jhaver, K., Hansen, A., Koni, P. A.,Iwashima, M., Munn, D. H. (2003). Cutting edge: induced indoleamine 2,3 dioxygenaseexpression in dendritic cell subsets suppresses T cell clonal expansion.J. Immunol.171: 1652-1655.
117. Mellor, A. L, Baban, B., Chandler, P. R., Manlapat, A., Kahler, D. J., Munn, D. H. (2005).Cutting edge: CpG oligonucleotides induce splenic CD19 + dendritic cells to acquirepotent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFNType 1 signaling. J. Immunol. 175: 5601-5605.
118. Mellor, A. L., Chandler, P., Baban, B., Hansen, A. M., Marshall, B., Pihkala, J.,Waldmann, H., Cobbold, S., Adams, E., Munn, D. H. (2004). Specific subsets ofmurine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int. Immunol.16: 1391-1401.
119. Mellor, A. L., Keskin, D. B., Johnson, T., Chandler, P., Munn, D. H. (2002). Cellsexpressing indoleamine 2,3-dioxygenase inhibit T cell responses. J. Immunol.168: 3771-3776.
120. Mellor, A. L., Munn, D. H. (2008). Creating immune privilege: active local suppressionthat benefits friends, but protects foes. Nat. Rev. Immunol. 8: 74-80.
121. Mellor, A. L., Munn, D. H. (2011). Physiologic control of the functional status of Foxp3 + regulatory T cells. J. Immunol. 186: 4535-4540.
122. Mellor, A. L., Sivakumar, J., Chandler, P., Smith, K., Molina, H., Mao, D., Munn, D. H.(2001). Prevention of T cell-driven complement activation and inflammation bytryptophan catabolism during pregnancy. Nat. Immunol. 2: 64-68.
123. Metz, R., Duhadaway, J. B., Kamasani, U., Laury-Kleintop, L., Muller, A. J.,Prendergast, G. C. (2007). Novel tryptophan catabolic enzyme IDO2 is the preferredbiochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compoundD-1-methyl-tryptophan. Cancer Res. 67: 7082-7087.
124. Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., Bradfield,C. A. (2010). An interaction between kynurenine and the aryl hydrocarbon receptorcan generate regulatory T cells. J. Immunol. 185: 3190-3198.
125. Miyazaki, T., Moritake, K., Yamada, K., Hara, N., Osago, H., Shibata, T., Akiyama, Y.,Tsuchiya, M. (2009). Indoleamine 2,3-dioxygenase as a new target for malignantglioma therapy. Laboratory investigation. J. Neurosurg. 111: 230-237.
126. Mohib, K., Wang, S., Guan, Q., Mellor, A. L., Sun, H., Du, C., Jevnikar, A. M. (2008).Indoleamine 2,3-dioxygenase expression promotes renal ischemia-reperfusioninjury. Am. J. Physiol. Renal Physiol. 295: F226-234.
127. Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E. (2005a). PrendergastGC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of thecancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med.11: 312-319.
128. Muller, A. J., DuHadaway, J. B., Jaller, D., Curtis, P., Metz, R., Prendergast, G. C. (2010).Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growthwith ethyl pyruvate. Cancer Res. 70: 1845-1853.
129. Muller, A. J., Malachowski, W. P., Prendergast, G. C. (2005b). Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-moleculeinhibitors. Expert Opin. Ther. Targets 9: 831-849.
130. Muller, A. J., Scherle, P. A. (2006). Targeting the mechanisms of tumoral immunetolerance with small-molecule inhibitors. Nat. Rev. Cancer 6: 613-625.
131. Muller, A. J., Sharma, M. D., Chandler, P. R., Duhadaway, J. B., Everhart, M. E.,Johnson, B. A., 3rd, Kahler, D. J., Pihkala, J., Soler, A. P., Munn, D. H.,Prendergast, G. C., Mellor, A. L. (2008). Chronic inflammation that facilitatestumor progression creates local immune suppression by inducing indoleamine 2,3dioxygenase. Proc. Natl. Acad. Sci. USA105: 17073-17078.
132. Munn, D. H., Mellor, A. L. (2007). Indoleamine 2,3-dioxygenase and tumor-inducedtolerance. J Clin Invest. 117: 1147-1154.
133. Munn, D. H., Mellor, A. L., Rossi, M., Young, J. W. (2005a). Dendritic cells have the optionto express IDO-mediated suppression or not. Blood 105: 2618.
134. Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I., Pashine, A., Mellor, A. L.(1999). Inhibition of T cell proliferation by macrophage tryptophan catabolism.J. Exp. Med. 189: 1363-1372.
135. Munn, D. H., Sharma, M. D., Baban, B., Harding, H. P., Zhang, Y., Ron, D., Mellor, A. L.(2005b). GCN2 kinase in T cells mediates proliferative arrest and anergy inductionin response to indoleamine 2,3-dioxygenase. Immunity 22: 633-642.
136. Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L.,Chandler, P., Koni, P. A., Mellor, A. L. (2004a). Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.J. Clin. Invest. 114: 280-290.
137. Munn, D. H., Sharma, M. D., Lee, J. R., Jhaver, K. G., Johnson, T. S., Keskin, D. B.,Marshall, B., Chandler, P., Antonia, S. J., Burgess, R., Slingluff, C. L., Jr., Mellor,A. L. (2000). Potential regulatory function of human dendritic cells expressingindoleamine 2,3-dioxygenase. Science 297: 1867-1870.
138. Munn, D. H., Sharma, M. D., Mellor, A. L. (2004b). Ligation of B7-1/B7-2 by human CD4 + T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol.172: 4100-110.
139. Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown,C., Mellor, A. L. (1998). Prevention of allogeneic fetal rejection by tryptophan catabolism.Science 281: 1191-1193.
140. Nakano, S., Takai, K., Isaka, Y., Takahashi, S., Unno, Y., Ogo, N., Matsuno, K.,Takikawa, O., Asai, A. ( ).Identification of novel kynurenine production-inhibitingbenzenesulfonamide derivatives in cancer cells. Biochem. Biophys. Res. Commun.419: 556-561.
141. Nelson, J. L., Furst, D. E., Maloney, S., Gooley, T., Evans, P. C., Smith, A., Bean, M. A.,Ober, C., Bianchi, D. W. (1998). Microchimerism and HLA-compatible relationshipsof pregnancy in scleroderma. Lancet 351: 559-562.
142. Nguyen, N. .T, Kimura, A., Nakahama, T., Chinen, I., Masuda, K., Nohara, K., Fujii-Kuriyama, Y., Kishimoto, T. (2010). Aryl hydrocarbon receptor negatively regulatesdendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc. Natl.Acad. Sci. USA 107: 19961-19966.
143. Ochsenbein, A. F., Klenerman, P., Karrer, U., Ludewig, B., Pericin, M., Hengartner, H.,Zinkernagel, R. M. (1999). Immune surveillance against a solid tumor fails becauseof immunological ignorance. Proc Natl Acad Sci USA 96: 2233-2238.
144. Odemuyiwa, S. O., Ebeling, C., Duta, V., Abel, M., Puttagunta, L., Cravetchi, O.,Majaesic, C., Vliagoftis, H., Moqbel, R. (2009). Tryptophan catabolites regulatemucosal sensitization to ovalbumin in respiratory airways. Allergy 64: 488-492.
145. Okamoto, A., Nikaido, T., Ochiai, K., Takakura, S., Saito, M., Aoki, Y., Ishii, N.,Yanaihara, N., Yamada, K., Takikawa, O., Kawaguchi, R., Isonishi, S., Tanaka, T.,Urashima, M. (2005). Indoleamine 2,3-dioxygenase serves as a marker of poor prognosisin gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res.11: 6030-6039.
146. Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S.,Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., Jugold, M., Guillemin, G. J.,Miller, C. L., Lutz, C., Radlwimmer, B., Lehmann, I., von Deimling, A., Wick, W.,Platten, M. (2011). An endogenous tumour-promoting ligand of the human arylhydrocarbon receptor. Nature 478: 197-203.
147. Orabona, C., Pallotta, M. T., Volpi, C., Fallarino, F., Vacca, C., Bianchi, R., Belladonna,M. L., Fioretti, M. C., Grohmann, U., Puccetti, P. (2008). SOCS3 drives proteasomaldegradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependenttolerogenesis. Proc. Natl. Acad. Sci. USA 105: 20828-2033.
148. Orabona, C., Puccetti, P., Vacca, C., Bicciato, S., Luchini, A., Fallarino, F., Bianchi, R.,Velardi, E., Perruccio, K., Velardi, A., Bronte, V., Fioretti, M. C., Grohmann, U.(2006). Toward the identification of a tolerogenic signature in IDO-competent dendriticcells. Blood 107: 2846-2854.
149. Paveglio, S. A., Allard, J., Foster Hodgkins, S. R., Ather, J. L., Bevelander, M., Campbell,J. M., Whittaker LeClair, L. A., McCarthy, S. M., van der Vliet, A., Suratt, B. T.,Boyson, J. E., Uematsu, S., Akira, S., Poynter, M. E. (2011). Airway epithelialindoleamine 2,3-dioxygenase inhibits CD4 + T cells during Aspergillus fumigatusantigen exposure. Am. J. Respir. Cell. Mol. Biol. 44: 11-23.
150. Peggs, K. S., Quezada, S. A., Allison, J. P. (2008). Cell intrinsic mechanisms of T-cellinhibition and application to cancer therapy. Immunol. Rev. 224: 141-165.
151. Pilotte, L., Larrieu, P., Stroobant, V., Colau, D., Dolusic, E., Frederick, R., De Plaen, E.,Uyttenhove, C., Wouters, J., Masereel, B., Van den Eynde, B. J. (in press). Reversalof tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc.Natl. Acad. Sci. USA.
152. Podsypanina, K., Li, Y., Varmus, H. E. (2004). Evolution of somatic mutations inmammary tumors in transgenic mice is influenced by the inherited genotype.BMC Med. 2: 24.
153. Polak, M. E., Borthwick, N. J., Gabriel, F. G., Johnson, P., Higgins, B., Hurren, J.,McCormick, D., Jager, M. J., Cree, I. A. (2007). Mechanisms of local immunosuppressionin cutaneous melanoma. Br J Cancer 96: 1879-1887.
154. Popov, A., Abdullah, Z., Wickenhauser, C., Saric, T., Driesen, J., Hanisch, F. G., Domann,E., Raven, E. L., Dehus, O., Hermann, C., Eggle, D., Debey, S., Chakraborty, T.,Kronke, M., Utermohlen, O., Schultze, J. L. (2006). Indoleamine 2,3-dioxygenaseexpressingdendritic cells form suppurative granulomas following Listeria monocytogenesinfection. J. Clin. Invest. 116: 3160-3170.
155. Potula, R., Poluektova, L., Knipe, B., Chrastil, J., Heilman, D., Dou, H., Takikawa, O.,Munn, D. H., Gendelman, H. E., Persidsky, Y. (2005). Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animalmodel of HIV-1 encephalitis. Blood 106: 2382-2390.
156. Powell, J. D., Delgoffe, G. M. (2010). The mammalian target of rapamycin: linking T celldifferentiation, function, and metabolism. Immunity 33: 301-311.
157. Qian, F., Villella, J., Wallace, P. K., Mhawech-Fauceglia, P., Tario, J. D., Jr., Andrews, C.,Matsuzaki, J., Valmori, D., Ayyoub, M., Frederick, P. J., Beck, A., Liao, J., Cheney,R., Moysich, K., Lele, S., Shrikant, P., Old, L. J., Odunsi, K. (2009). Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovariancancer. Cancer Res. 69: 5498-5504.
158. Quezada, S. A., Peggs, K. S., Simpson, T. R., Allison, J. P. (2011). Shifting the equilibriumin cancer immunoediting: from tumor tolerance to eradication. Immunol. Rev.241: 104-118.
159. Quezada, S. A., Peggs, K. S., Simpson, T. R., Shen, Y., Littman, D. R., Allison, J. P. (2008).Limited tumor infiltration by activated T effector cells restricts the therapeuticactivity of regulatory T cell depletion against established melanoma. J. Exp. Med.205: 2125-2138.
160. Quintana, F. J., Basso, A. S., Iglesias, A. H., Korn, T., Farez, M. F., Bettelli, E., Caccamo,M., Oukka, M., Weiner, H. L. (2008). Control of T(reg) and T(H)17 cell differentiationby the aryl hydrocarbon receptor. Nature 453: 65-71.
161. Ramakrishnan, R., Antonia, S., Gabrilovich, D. I. (2008). Combined modality immunotherapyand chemotherapy: a new perspective. Cancer Immunol. Immunother.257: 1523-1529.
162. Ratajczak, P., Janin, A., Peffault de Larour, R., Koch, L., Roche, B., Munn, D., Blazar,B. R., Socie, G. (2012). IDO in human gut graft-vs-host disease. Biol Blood MarrowTransplant. 18: 150-155.
163. Ravishankar, B., Liu, H., Shinde, R., Chandler, P., Baban, B., Tanaka, M., Munn, D. H.,Mellor, A. L., Karlsson, M. C., McGaha, T. L. (2012) Tolerance to apoptotic cells isregulated by indoleamine 2,3-dioxygenase. Proc. Natl. Acad. Sci. USA, in press.
164. Ribas, A., Comin-Anduix, B., Economou, J. S., Donahue, T. R., de la Rocha, P., Morris,L. F., Jalil, J., Dissette, V. B., Shintaku, I. P., Glaspy, J. A., Gomez-Navarro, J.,Cochran, A. J. (2009). Intratumoral immune cell infiltrates, FoxP3, and indoleamine2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin.Cancer Res. 15: 390-399.
165. Rodriguez, P. C., Quiceno, D. G., Ochoa, A. C. (2007). L-arginine availability regulates Tlymphocytecell-cycle progression. Blood 109: 1568-1573.
166. Romani, L., Fallarino, F., De Luca, A., Montagnoli, C.,D'Angelo, C., Zelante, T., Vacca, C.,Bistoni, F., Fioretti, M. C., Grohmann, U., Segal, B. H., Puccetti, P. (2008). Defectivetryptophan catabolism underlies inflammation in mouse chronic granulomatousdisease. Nature 451: 211-215.
167. Rutella, S., Bonanno, G., Procoli, A., Mariotti, A., de Ritis, D. G., Curti, A., Danese, S.,Pessina, G., Pandolfi, S., Natoni, F., Di Febo, A., Scambia, G., Manfredini, R., Salati,S., Ferrari, S., Pierelli, L., Leone, G., Lemoli, R. M. (2010). Hepatocyte growth factorfavors monocyte differentiation into regulatory interleukin (IL)-10 + +IL-12low/negaccessory cells with dendritic-cell features. Blood 108: 218-227.
168. Schreiber, H., Rowley, D. A. (2010). Cancer. Awakening immunity. Science 330: 761-762.
169. Schreiber, R. D., Old, L. J., Smyth, M. J. (2011). Cancer immunoediting: integratingimmunity's roles in cancer suppression and promotion. Science 331: 1565-1570.
170. Sharma, M. D., Baban, B., Chandler, P., Hou, D. Y., Singh, N., Yagita, H., Azuma, M.,Blazar, B. R., Mellor, A. L., Munn, D. H. (2007). Plasmacytoid dendritic cells frommouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine2,3-dioxygenase. J. Clin. Invest.117: 2570-2582.
171. Sharma, M. D., Hou, D. Y., Baban, B., Koni, P. A., He, Y., Chandler, P. R., Blazar, B. R.,Mellor, A. L., Munn, D. H. (2010). Reprogrammed foxp3( +) regulatory T cells provideessential help to support cross-presentation and CD8( +) T cell priming in naive mice.Immunity 33: 942-954.
172. Sharma, M. D., Hou, D. Y., Liu, Y., Koni, P. A., Metz, R., Chandler, P., Mellor, A. L., He,Y., Munn, D. H. (2009). Indoleamine 2,3-dioxygenase controls conversion of Foxp3 + Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 113: 6102-6111.
173. Shields, J. D., Kourtis, I. C., Tomei, A. A., Roberts, J. M., Swartz, M. A. (2010). Inductionof lymphoidlike stroma and immune escape by tumors that express the chemokineCCL21. Science 328: 749-752.
174. Soliman, H., Mediavilla-Varela, M., Antonia, S. (2010). Indoleamine 2,3-dioxygenase: isit an immune suppressor? Cancer J. 16: 354-359.
175. Soliman, H. H., Antonia, S. J., Sullivan, D., Vanahanian, N., Link, C. (2009). Overcomingtumor antigen anergy in human malignancies using the novel indeolamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT). J. Clin. Oncol.27: 3004.
176. Sotomayor, E. M., Borrello, I., Rattis, F. M., Cuenca, A. G., Abrams, J., Staveley-O'Carroll, K., Levitsky, H. I. (2001). Cross-presentation of tumor antigens by bonemarrow-derived antigen-presenting cells is the dominant mechanism in the inductionof T-cell tolerance during B-cell lymphoma progression. Blood 98: 1070-1077.
177. Spiotto, M. T., Yu, P., Rowley, D. A., Nishimura, M. I., Meredith, S. C., Gajewski, T. F., Fu,Y. X., Schreiber, H. (2002). Increasing tumor antigen expression overcomes "ignorance"to solid tumors via crosspresentation by bone marrow-derived stromal cells.Immunity 17: 737-747.
178. Stone, T. W., Darlington, L. G. (2002). Endogenous kynurenines as targets for drugdiscovery and development. Nat. Rev. Drug Discov. 1: 609-620.
179. Sugimoto, H., Oda, S., Otsuki, T., Hino, T., Yoshida, T., Shiro, Y. (2006). Crystal structureof human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation bya heme-containing dioxygenase. Proc. Natl. Acad. Sci. USA 103: 2611-2616.
180. Sundrud, M. S., Koralov, S. B., Feuerer, M., Calado, D. P., Kozhaya, A. E., Rhule-Smith,A., Lefebvre, R. E., Unutmaz, D., Mazitschek, R., Waldner, H., Whitman, M., Keller,T., Rao, A. (2009). Halofuginone inhibits TH17 cell differentiation by activating theamino acid starvation response. Science 2009;324: 1334-1338.
181. Sung, V., Venkateshan, C. N., Williamson, L., Ward, R., Espey, M. G., Gibbs, C. J., Jr.,Moffett, J. R., Namboodiri, M. A. (1997). Immuno-electron microscopy reveals thatthe excitotoxin quinolinate is associated with the plasma membrane in humanperipheral blood monocytes/macrophages. Cell Tissue Res. 290: 633-639.
182. Swanson, K. A., Zheng, Y., Heidler, K. M., Mizobuchi, T., Wilkes, D. S. (2004). CDllc + cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am. J. Respir. Cell Mol. Biol. 30: 311-318.
183. Tas, S. W., Vervoordeldonk, M. J., Hajji, N., Schuitemaker, J. H., van der Sluijs, K. F.,May, M. J., Ghosh, S., Kapsenberg, M. L., Tak, P. P., de Jong, E. C. (2007).Noncanonical NF-kappaB signaling in dendritic cells is required for indoleamine2,3-dioxygenase (IDO) induction and immune regulation. Blood 110: 1540-1549.
184. Taylor, M. W., Feng, G. S. (1991). Relationship between interferon-gamma, indoleamine2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5: 2516-2522.
185. Terness, P., Chuang, J. J., Bauer, T., Jiga, L., Opelz, G. (2005). Regulation of human autoandalloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendriticcells: too much ado about IDO? Blood 105: 2480-2486.
186. Thebault, P., Condamine, T., Heslan, M., Hill, M., Bernard, I., Saoudi, A., Josien, R.,Anegon, I., Cuturi, M. C., Chiffoleau, E. (2007). Role of IFNgamma in allografttolerance mediated by CD4 +CD25 + regulatory T cells by induction of IDO inendothelial cells. Am. J. Transplant. 7: 2472-2482.
187. Thomas, S. M., Garrity, L. F., Brandt, C. R., Schobert, C. S., Feng, G. S., Taylor, M. W.,Carlin, J. M., Byrne, G. I. (1993). IFN-gamma-mediated antimicrobial response.Indoleamine 2,3-dioxygenase-deficient mutant host cells no longer inhibit intracellularChlamydia spp. or Toxoplasma growth. J. Immunol. 150: 5529-5534.
188. Uyttenhove, C., Pilotte, L., Theate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T.,Van den Eynde, B. J. (2003). Evidence for a tumoral immune resistance mechanismbased on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med.9: 1269-1274.
189. Vacca, C., Fallarino, F., Perruccio, K., Orabona, C., Bianchi, R., Gizzi, S., Velardi, A.,Fioretti, M.C., Puccetti, P., Grohmann, U. (2005). CD40 ligation prevents onset oftolerogenic properties in human dendritic cells treated with CTLA-4-Ig. MicrobesInfect. 7: 1040-1048.
190. van der Marel, A. P., Samsom, J. N., Greuter, M., van Berkel, L. A., O'Toole, T., Kraal, G.,Mebius, R. E. (2007). Blockade of IDO inhibits nasal tolerance induction.J. Immunol. 179: 894-900.
191. Vence, L., Palucka, A. K., Fay, J. W., Ito, T., Liu, Y. J., Banchereau, J., Ueno, H. (2007).Circulating tumor antigen-specific regulatory T cells in patients with metastaticmelanoma. Proc Natl Acad Sci USA 104: 20884-20889.
192. Vogel, C. F., Goth, S. R., Dong, B., Pessah, I. N., Matsumura, F. (2008). Aryl hydrocarbonreceptor signaling mediates expression of indoleamine 2,3-dioxygenase. Biochem.Biophys. Res. Commun. 375: 331-335.
193. von Bergwelt-Baildon, M. S., Popov, A., Saric, T., Chemnitz, J., Classen, S., Stoffel, M. S.,Fiore, F., Roth, U., Beyer, M., Debey, S., Wickenhauser, C., Hanisch, F. G., Schultze,J. L. (2006). CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandinE2 and expressed by tumor-associated dendritic cells in vivo: additional mechanismsof T-cell inhibition. Blood 108: 228-237.
194. Wek, R. C., Jiang, H. Y., Anthony, T. G. (2006). Coping with stress: eIF2 kinases andtranslational control. Biochem. Soc. Trans. 34: 7-11.
195. Williams, K. M., Hakim, F. T. (2007). Gress RE. T cell immune reconstitution followinglymphodepletion. Semin. Immunol. 19: 318-330.
196. Willimsky, G., Blankenstein, T. (2005). Sporadic immunogenic tumours avoid destructionby inducing T-cell tolerance. Nature 437: 141-146.
197. Willimsky, G., Czeh, M., Loddenkemper, C., Gellermann, J., Schmidt, K., Wust, P.,Stein, H., Blankenstein, T. (2008). Immunogenicity of premalignant lesions is theprimary cause of general cytotoxic T lymphocyte unresponsiveness. J. Exp. Med.205: 1687-1700.
198. Witkiewicz, A., Williams, T. K., Cozzitorto, J., Durkan, B., Showalter, S. L., Yeo, C. J.,Brody, J. R. (2008). Expression of indoleamine 2,3-dioxygenase in metastatic pancreaticductal adenocarcinoma recruits regulatory T cells to avoid immune detection.J. Am. Coll. Surg. 206: 849-854; discussion 854-6.
199. Witkiewicz, A. K., Costantino, C. L., Metz, R., Muller, A. J., Prendergast, G. C., Yeo, C. J.,Brody, J. R. (2009). Genotyping and expression analysis of IDO2 in human pancreaticcancer: a novel, active target. J. Am. Coll. Surg. 208: 781-787; discussion 787-789.
200. Wobser, M., Voigt, H., Houben, R., Eggert, A. O., Freiwald, M., Kaemmerer, U.,Kaempgen, E., Schrama, D., Becker, J. C. (2007). Dendritic cell based antitumorvaccination: impact of functional indoleamine 2,3-dioxygenase expression. CancerImmunol. Immunother. 56: 1017-1024.
201. Yan, M. L., Wang, Y. D., Tian, Y. F., Lai, Z. D., Yan, L. N. (2010a). Inhibition of allogeneicT-cell response by Kupffer cells expressing indoleamine 2,3-dioxygenase. WorldJ. Gastroenterol. 16: 636-640.
202. Yan, Y., Zhang, G. X., Gran, B., Fallarino, F., Yu, S., Li, H., Cullimore, M. L., Rostami, A.,Xu, H. (2010b). IDO upregulates regulatory T cells via tryptophan catabolite andsuppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis.J. Immunol. 185: 5953-5961.
203. Yu, J., Sun, J., Wang, S. E., Li, H., Cao, S., Cong, Y., Liu, J., Ren, X. (2011). Upregulatedexpression of indoleamine 2, 3-dioxygenase in primary breast cancer correlates withincrease of infiltrated regulatory T cells in situ and lymph node metastasis. Clin.Dev. Immunol. 2011: 1-10.
204. Yu, P., Lee, Y., Liu, W., Krausz, T., Chong, A., Schreiber, H., Fu, Y. X. (2005). Intratumordepletion of CD4 + cells unmasks tumor immunogenicity leading to the rejection oflate-stage tumors. J. Exp. Med. 201: 779-791.
205. Yuan, W., Collado-Hidalgo, A., Yufit, T., Taylor, M., Varga, J. (1998). Modulation ofcellular tryptophan metabolism in human fibroblasts by transforming growth factorbeta: selective inhibition of indoleamine 2,3-dioxygenase and tryptophanyl-tRNAsynthetase gene expression. J. Cell Physiol. 177: 174-186.
206. Yue, E. W., Douty, B., Wayland, B., Bower, M., Liu, X., Leffet, L., Wang, Q.,Bowman, K. J., Hansbury, M. J., Liu, C., Wei, M., Li, Y., Wynn, R., Burn,T. C., Koblish, H. K., Fridman, J. S., Metcalf, B., Scherle, P. A., Combs, A. P.(2009). Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mousemelanoma model. J. Med. Chem. 52: 7364-7367.
207. Zhang, B., Bowerman, N. A., Salama, J. K., Schmidt, H., Spiotto, M. T., Schietinger, A.,Yu, P., Fu, Y. X., Weichselbaum, R. R., Rowley, D. A., Kranz, D. M., Schreiber, H.(2007). Induced sensitization of tumor stroma leads to eradication of establishedcancer by T cells. J. Exp. Med. 204: 49-55.
208. Zhang, G., Liu, W. L., Zhang, L., Wang, J. Y., Kuang, M. H., Liu, P., Lin, Y. H., Dai, S. Q.,Du, J. (2011). Involvement of indoleamine 2,3-dioxygenase in impairing tumorinfiltratingCD8 T-cell functions in esophageal squamous cell carcinoma. Clin. Dev.Immunol. 2011: 1-12.
209. Zhou, G., Drake, C. G., Levitsky, H. I. (2006). Amplification of tumor-specific regulatory Tcells following therapeutic cancer vaccines. Blood 107: 628-636.
210. Zitvogel, L., Apetoh, L., Ghiringhelli, F., Andre, F., Tesniere, A., Kroemer, G. (2008a). Theanticancer immune response: indispensable for therapeutic success? J. Clin. Invest.118: 1991-2001.
211. Zitvogel, L., Apetoh, L., Ghiringhelli, F., Kroemer, G. (2008b). Immunological aspects ofcancer chemotherapy. Nat. Rev. Immunol. 8: 59-73.